Sanara MedTech (NASDAQ:SMTI) Posts Quarterly Earnings Results

Sanara MedTech (NASDAQ:SMTI) released its earnings results on Tuesday. The company reported ($0.19) earnings per share for the quarter, FiscalAI reports. Sanara MedTech had a negative return on equity of 21.33% and a negative net margin of 36.79%.The firm had revenue of $27.55 million during the quarter.

Here are the key takeaways from Sanara MedTech’s conference call:

• Revenue milestone: Sanara exceeded $100 million of net revenue in 2025 ($103.1M, +19% YoY) while maintaining a roughly 40-person field sales force, highlighting scalability of its hybrid commercial model.
• Profitability and cash generation improved: Full-year gross margin expanded to ~93% (~200 bps improvement), adjusted EBITDA rose to $17M (+86% YoY), and cash from operations was $6.8M versus $24K used in 2024.
• Distribution catalyst — BIASURGE won Vizient’s Innovative Technology contract effective Jan 1, 2026, providing access to ~1,800 facilities and a meaningful commercial runway for adoption.
• Forward visibility — management introduced and reaffirmed 2026 net revenue guidance of $116M–$121M (13%–17% growth) and Q1 revenue guidance of ~$26.7M–$27.2M, signaling confidence in near-term execution.
• Balance sheet and expense risks — cash was $16.6M while long-term debt increased to $46M, Q4 continuing-operations net loss was $1.1M, and operating expenses rose partly due to a $1.8M non-cash IP impairment, indicating leverage and near-term cost headwinds.

Sanara MedTech Price Performance

Shares of SMTI opened at $18.08 on Wednesday. The business’s 50-day moving average is $20.36 and its 200-day moving average is $24.67. The company has a debt-to-equity ratio of 7.34, a current ratio of 1.80 and a quick ratio of 1.60. The company has a market capitalization of $160.91 million, a price-to-earnings ratio of -4.28 and a beta of 1.04. Sanara MedTech has a fifty-two week low of $17.54 and a fifty-two week high of $35.95.

Analysts Set New Price Targets

Several brokerages recently commented on SMTI. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of Sanara MedTech in a research report on Monday, January 26th. Zacks Research downgraded shares of Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sanara MedTech in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $41.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Sanara MedTech by 3.4% in the 3rd quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after buying an additional 6,049 shares during the period. Stonebridge Wealth Management LLC grew its holdings in shares of Sanara MedTech by 17.8% during the 4th quarter. Stonebridge Wealth Management LLC now owns 134,934 shares of the company’s stock valued at $3,151,000 after acquiring an additional 20,353 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of Sanara MedTech by 127.3% during the 4th quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock valued at $2,747,000 after acquiring an additional 65,887 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sanara MedTech by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 79,049 shares of the company’s stock valued at $1,846,000 after acquiring an additional 546 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Sanara MedTech by 144.3% in the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after acquiring an additional 42,237 shares during the last quarter. 8.10% of the stock is owned by hedge funds and other institutional investors.

Key Sanara MedTech News

Here are the key news stories impacting Sanara MedTech this week:

• Positive Sentiment: Sanara reaffirmed full‑year 2026 financial guidance and reported Q4 revenue up ~5% to $27.5M, signaling stable top‑line momentum that likely reassured investors. GlobeNewswire Release
• Positive Sentiment: Market coverage noted a positive intraday reaction — multiple outlets reported SMTI shares rising ~3% despite the earnings miss, suggesting investor focus on revenue/guidance over the headline EPS. MSN Article
• Neutral Sentiment: Q4 earnings call transcript and conference materials are available for investors who want details on drivers and guidance; review the call for management’s explanations on margins, product trends and 2026 assumptions. Earnings Call Transcript
• Neutral Sentiment: Multiple short‑interest notices claim a “large increase” for March, but the published figures show 0 shares/NaN and inconsistent days‑to‑cover values — the short‑interest data appears erroneous and does not provide a reliable signal. (Data vendor notices published 3/24.)
• Negative Sentiment: Q4 results missed consensus estimates — Zacks reported EPS of $0.04 vs. a $0.11 estimate (and other summaries show differing EPS figures), creating headline risk and confusion that pressured sentiment. Zacks Earnings Miss
• Negative Sentiment: Fundamental headwinds remain: negative net margin and ROE, and a high debt‑to‑equity (~7.3) increase financial risk and may limit upside until profitability trends improve (from public filings/market data).

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.